Eli Lilly and Company (NYSE:LLY) Shares Purchased by SYM FINANCIAL Corp

SYM FINANCIAL Corp grew its stake in Eli Lilly and Company (NYSE:LLY) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,141 shares of the company’s stock after acquiring an additional 364 shares during the quarter. Eli Lilly and Company comprises approximately 0.6% of SYM FINANCIAL Corp’s portfolio, making the stock its 18th biggest holding. SYM FINANCIAL Corp’s holdings in Eli Lilly and Company were worth $3,580,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in LLY. Connecticut Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 5.3% in the fourth quarter. Connecticut Wealth Management LLC now owns 3,040 shares of the company’s stock valued at $1,772,000 after buying an additional 154 shares in the last quarter. Avidian Wealth Solutions LLC boosted its holdings in Eli Lilly and Company by 4.1% in the fourth quarter. Avidian Wealth Solutions LLC now owns 2,944 shares of the company’s stock valued at $1,716,000 after purchasing an additional 116 shares during the last quarter. Avalon Trust Co increased its holdings in Eli Lilly and Company by 36.7% during the 4th quarter. Avalon Trust Co now owns 995 shares of the company’s stock worth $580,000 after purchasing an additional 267 shares during the last quarter. Forte Capital LLC ADV increased its stake in shares of Eli Lilly and Company by 7.0% in the fourth quarter. Forte Capital LLC ADV now owns 1,640 shares of the company’s stock worth $956,000 after buying an additional 108 shares during the last quarter. Finally, Resolute Wealth Strategies LLC grew its stake in Eli Lilly and Company by 6.9% in the fourth quarter. Resolute Wealth Strategies LLC now owns 724 shares of the company’s stock worth $422,000 after purchasing an additional 47 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Wells Fargo & Company increased their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Finally, Barclays boosted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $20.94 during trading hours on Friday, reaching $734.97. 4,595,138 shares of the company were exchanged, compared to its average volume of 2,629,045. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90. The stock has a 50-day moving average of $761.06 and a 200 day moving average of $671.38. The firm has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.62 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.